ETR:MOR MorphoSys (MOR) Stock Price, News & Analysis €67.25 0.00 (0.00%) (As of 08/20/2024) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlines About MorphoSys Stock (ETR:MOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MorphoSys alerts:Sign Up Key Stats Today's Range€66.70▼€67.3050-Day Range€67.00▼€67.2552-Week Range€14.52▼€69.75Volume5,144 shsAverage Volume153,687 shsMarket Capitalization$2.53 billionP/E RatioN/ADividend Yield1.26%Price TargetN/AConsensus RatingN/A Company OverviewMorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More… Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address MOR Stock News HeadlinesBiogen refreshes its C-suite; Novartis writes down MorphoSys assetsOctober 29, 2024 | finance.yahoo.comNovartis says more time needed for cancer therapy added with MorphoSys dealOctober 29, 2024 | msn.com[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some readers walked away with gains as high as 459%, 646% even 700% - while the stock market got cut in half. You don't want to ignore his latest warning.November 2, 2024 | Behind the Markets (Ad)JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the DomainOctober 22, 2024 | finance.yahoo.comERAS Sep 2024 2.500 put (ERAS240920P00002500)August 28, 2024 | finance.yahoo.comMORF Sep 2024 40.000 put (MORF240920P00040000)August 17, 2024 | finance.yahoo.comLatest News for MorphoSys Stock (NASDAQ:MOR)May 17, 2024 | benzinga.comMorphoSys gains after Novartis discloses all tender offer conditions were metMay 16, 2024 | msn.comSee More Headlines MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed this year? MorphoSys' stock was trading at €34.00 at the beginning of the year. Since then, MOR stock has increased by 97.8% and is now trading at €67.25. View the best growth stocks for 2024 here. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), SolarEdge Technologies (SEDG), Gilead Sciences (GILD), AbbVie (ABBV) and Abbott Laboratories (ABT). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolETR:MOR CUSIPN/A CIKN/A Webwww.morphosys.de Phone+49-89-899270FaxN/AEmployees730Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€5.53) Trailing P/E RatioN/A Forward P/E Ratio322.58 P/E Growth0.06Net Income$-468,570,000.00 Net Margins-190.61% Pretax MarginN/A Return on Equity-183.80% Return on Assets-13.84% Debt Debt-to-Equity Ratio3,454.18 Current Ratio1.38 Quick Ratio3.49 Sales & Book Value Annual Sales$241.47 million Price / Sales10.49 Cash Flow€129.73 per share Price / Cash Flow0.52 Book Value(€6.96) per share Price / Book-9.66Miscellaneous Outstanding Shares37,660,000Free FloatN/AMarket Cap$2.53 billion OptionableNot Optionable Beta0.66 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (ETR:MOR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.